Congress Explores Remedies For Corporate Tax Inversion “Fever”
This article was originally published in The Rose Sheet
Executive Summary
Senate Finance Committee Chairman Wyden questions the suggestion that drug manufacturers’ corporate tax inversions lead to lower health-care costs in the U.S. Inversion transactions have been on the rise since Helen of Troy’s landmark reorganization in the early 1990s in Bermuda, with President Obama recently casting firms that move their businesses overseas for tax benefits as “corporate deserters.”